Drugs / Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04094766 | Aug 2017 → Aug 2020 | B-cell acute lymphoblastic leukemia | Second Affiliated Hospital of Xi'an Jiaotong University | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04094766 ↗ |
| Action | Deplete | “The dual specificity CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.” NCT04094766 ↗ |
| Modality | Cell therapy | “patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy” NCT04094766 ↗ |
| Route | Intravenous | “by intravenous injection” NCT04094766 ↗ |